The research will examine the tolerability, security, pharmacodynamics, pharmacokinetics and results of TG and LDL-C in 78 topics with blended hyperlipidemia. Credit score: Gorodenkoff/Shutterstock.com. Arrowhead Prescribed drugs has dosed the primary individuals within the Section I/IIa scientific trial of ARO-DIMER-PA, an investigational dual-functional RNA interference (RNAi) remedy, for blended hyperlipidemia. The placebo-controlled, dose-escalating ARO-DIMER-PA-1001 research goals to evaluate the remedy […]